LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kevin Knopf, Dr. Sandip Patel, and Dr. Balazs Halmos discuss the practice-changing impact of ASCO presentations in lung cancer.
On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top lung cancer clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8, 2021. Dr. Kevin Knopf from the University of California, San Francisco moderated the discussion between lung cancer KOLs Dr. Sandip Patel from the University of California, San Diego and Dr. Balazs Halmos from Albert Einstein College of Medicine.
The discussion covered ASCO abstract #8500 IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC), ASCO asbstract #9013 Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm), and ASCO abstract #3008 BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including lung cancer. Click below to read more about them and watch their video analysis.
Navigating the busy world of pharmaceutical conferences can be a daunting task, filled with endless sessions, abstracts, and updates to keep track of. This is where LARVOL CONF comes into play – offering a simple, yet powerful way to organize and manage conference information effectively.
The global pandemic caused by COVID-19 has cast a profound impact on nearly every aspect of our lives. Its effects on health, economics, education, and social structures are apparent, but there are less visible but equally significant impacts too.